Can immune aging blood tests predict which older IBD patients thrive on advanced therapies?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 60 years or older, regardless of sex. Confirmed diagnosis of Crohn disease, ulcerative colitis, or inflammatory bowel disease-unclassified based on standard clinical, endoscopic, imaging, histologic, and laboratory criteria. Planning to initiate, or having initiated within the previous 4 weeks, a new advanced therapy, including vedolizumab, ustekinumab, an anti-TNF agent, a JAK inhibitor, an S1P receptor modulator, or another approved or clinically available advanced therapy. Active IBD or a clear indication for treatment escalation at the time of advanced therapy initiation. Availability of core baseline clinical and laboratory assessments required for the study. Expected ability to complete at least 52 weeks of follow-up. Ability of the participant or legally authorized representative to understand the study and provide written informed consent. Exclusion Criteria: * Uncertain diagnosis of IBD or another condition more likely to explain intestinal inflammation. Active severe infection at enrollment, including sepsis, active tuberculosis, uncontrolled viral hepatitis, active cytomegalovirus colitis, or another serious opportunistic infection. Clinically significant acute infection within 4 weeks before enrollment that may substantially affect baseline immune-aging measurements or short-term safety assessment. Active malignancy or recent systemic treatment for malignancy, except for adequately treated low-risk cancers as judged by the investigator. Severe immunodeficiency unrelated to IBD. Expected survival of less than 12 months or another severe end-stage condition likely to interfere with follow-up or interpretation of outcomes. Inability to obtain core baseline variables within the predefined assessment window. Continuous use of the same advanced therapy for more than 4 weeks before enrollment. Participation in another interventional study that may substantially affect treatment effectiveness or safety assessment. Any other condition that, in the investigator's judgment, would make participation inappropriate or compromise follow-up or data quality.